Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy
- 15 April 2010
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 84 (8), 3835-3844
- https://doi.org/10.1128/jvi.01553-09
Abstract
Newcastle disease virus (NDV), an avian paramyxovirus, is tumor selective and intrinsically oncolytic because of its potent ability to induce apoptosis. Several studies have demonstrated that NDV is selectively cytotoxic to tumor cells but not normal cells due to defects in the interferon (IFN) antiviral responses of tumor cells. Many naturally occurring strains of NDV have an intact IFN-antagonistic function and can still replicate in normal human cells. To avoid potential toxicity issues with NDV, especially in cancer patients with immunosuppression, safe NDV-oncolytic vectors are needed. We compared the cell killing abilities of (i) a recombinant NDV (rNDV) strain, Beaudette C, containing an IFN-antagonistic, wild-type V protein (rBC), (ii) an isogenic recombinant virus with a mutant V protein (rBC-Edit virus) that induces increased IFN in infected cells and whose replication is restricted in normal human cells, and (iii) a recombinant LaSota virus with a virulent F protein cleavage site that is as interferon sensitive as rBC-Edit virus (LaSota V.F. virus). Our results indicated that the tumor-selective replication of rNDV is determined by the differential regulation of IFN-α and downstream antiviral genes induced by IFN-α, especially through the IRF-7 pathway. In a nude mouse model of human fibrosarcoma, we show that the IFN-sensitive NDV variants are as effective as IFN-resistant rBC virus in clearing the tumor burden. In addition, mice treated with rNDV exhibited no signs of toxicity to the viruses. These findings indicate that augmentation of innate immune responses by NDV results in selective oncolysis and offer a novel and safe virotherapy platform.Keywords
This publication has 46 references indexed in Scilit:
- Genetically engineered Newcastle disease virus for malignant melanoma therapyGene Therapy, 2009
- Use of Reverse Genetics to Enhance the Oncolytic Properties of Newcastle Disease VirusCancer Research, 2007
- Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapyCancer Gene Therapy, 2007
- Newcastle Disease Virus Exerts Oncolysis by both Intrinsic and Extrinsic Caspase-Dependent Pathways of Cell DeathJournal of Virology, 2006
- PKR and RNase L Contribute to Protection against Lethal West Nile Virus Infection by Controlling Early Viral Spread in the Periphery and Replication in NeuronsJournal of Virology, 2006
- Differentially Regulated Interferon Response Determines the Outcome of Newcastle Disease Virus Infection in Normal and Tumor Cell LinesJournal of Virology, 2006
- Toward a New Generation of Conditionally Replicating Adenoviruses: Pairing Tumor Selectivity with Maximal OncolysisHuman Gene Therapy, 2002
- Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus TherapyJNCI Journal of the National Cancer Institute, 1994
- Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor- and Augmentation of Its Cytotoxicity2JNCI Journal of the National Cancer Institute, 1988
- Interferon Production in Mouse Spleen Cells and Mouse Fibroblasts (L Cells) Stimulated by Various Strains of Newcastle Disease VirusJournal of General Virology, 1982